English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background: Chemoresistance is a major clinical challenge facing oesophageal adenocarcinoma (OAC) patients, as 70% don’t respond to current treatments. Combining immune checkpoint inhibitors (ICIs) to boost responses is a therapeutic option of emerging interest. ICIs block IC receptors on T cells and ligands on cancer cells, reinvigorating anti-tumour immunity and blocking tumour cell-intrinsic survival signalling, respectively. Methods: In vitro, OE33 and SKGT4 cells (OAC cells) were used to: (I) assess basal expression of Ics; (II) examine the effect of combination chemotherapeutic regimens, (FLOT:5-fluorouracil, oxaliplatin and docetaxel, MAGIC:epirubicin, cisplatin and 5-fluoruracil and CROSS:paclitaxel, carboplatin) on (I) IC expression (n=3), (II) OAC stemness by assessing aldehyde dehydrogenase (ALDH) and CD54 expression (III) co-expression of ICs on cancer stem cells (CSCs) (n=3). Results: In vitro, inhibitory IC receptors including PD-1, TIGIT, TIM-3, LAG-3, CD160, PD-L1, PD-L2 and A2aR were identified basally on OAC cells. FLOT, MAGIC and CROSS significantly (P<0.05) upregulated ICs. All regimens enhanced a CSC phenotype demonstrated by upregulation of stemness markers ALDH and CD54 in vitro on OAC cells. PD-L1, PD-L2, TIM-3 and LAG-3 inhibitory ICs were significantly increased on stem-like OAC cells following FLOT, MAGIC and CROSS treatment in vitro. Conclusions: This data demonstrate the induction of ICs by chemotherapy regimens, an effect potentially promoting immune-resistance. A CSC phenotype is augmented by these treatments. Several studies demonstrate that blocking ICs on cancer cells enhances chemotherapy toxicity. This suggests that combining immunotherapy and chemotherapy as a multi-modal approach could prevent immune dysfunction and limit treatment resistance resulting in improved responses.

mesentery and peritoneum

AB065. First line chemotherapy regimens used in oesophageal adenocarcinoma promote immune dysfunction and enhance a cancer stem-like phenotype: potential implications for chemoimmuno resistance and novel multi-modal treatment regimens